GOSS News
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...
Business Wire
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...
Business Wire
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...
Business Wire
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today...
Business Wire
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today...
Business Wire
Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...
Business Wire
Gossamer’s Billion-Dollar Drug Bet Funded with $150M War Chest to Target FDA Approval
Gossamer Bio (NASDAQ:GOSS) is putting serious money behind a high-stakes regulatory bet. The company announced a structured private placement that could deliver up to $250 million, including $150 million of committed capital, as Gossamer races toward a planned September 2026 FDA submission for seralutinib in pulmonary arterial hypertension (PAH). The structure is milestone-driven: roughly $25 million is expected at the initial closing, another $125 million becomes available if the FDA accepts the NDA in 2026, and warrants could provide up to another $100 million if seralutinib ultimately receives FDA approval.
24-7 Market News
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...
Business Wire
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...
Business Wire
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks